The Zacks Analyst Blog Highlights: Bayer, Biogen Idec, Conceptus, Microsoft
and J. C. Penney
CHICAGO, May 7, 2013
CHICAGO, May 7, 2013 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Bayer (OTC:BAYRY), Biogen Idec
Inc. (Nasdaq:BIIB), Conceptus Inc. (Nasdaq:CPTS), Microsoft Corp.
(Nasdaq:MSFT) and J. C. Penney Company Inc. (NYSE:JCP).
Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Monday's Analyst Blog:
Bayer Discontinues Hemophilia Study
Bayer's (OTC:BAYRY) HealthCare segment recently decided to discontinue the
phase II/III TRUST (TReatment with Unique recombinant rFVIIa STudy) study on
BAY 86-6150. The study was evaluating the efficacy and safety of the candidate
in patients suffering from hemophilia A or hemophilia B with inhibitors.
Bayer stated that a neutralizing antibody was detected during the course of
the study. Since patient safety was the primary objective of the study, the
company discontinued the BAY 86-6150 trial as a precautionary measure.
Bayer already has Kogenate in its product portfolio for the treatment of
haemophilia. The drug generated around €1.2 billion in revenues during 2012.
Bayer also has BAY 94-9027 (rFVIII mutein) in its pipeline targeting
hemophilia A. The candidate is currently in phase III development.
We note that companies like Biogen Idec Inc. (Nasdaq:BIIB) are also developing
therapies targeting the hemophilia market.
Bayer was recently in the news when it inked a deal to buy Conceptus Inc.
(Nasdaq:CPTS) for $31.00 per share or approximately $1.1 billion in cash.
Bayer intends to launch a public tender soon to acquire all shares of
Conceptus. The transaction is expected to close by mid-2013.
Bayer's impending acquisition of Conceptus will add the Essure permanent
(non-surgical) birth control system to its product portfolio. We note that
Conceptus' Essure procedure was approved in 2002 in the US and is well
accepted in the market.
Bayer, a large cap pharma company, presently carries a Zacks Rank #4 (Sell).
European Schools Adopt Office 365
The world's largest software maker Microsoft Corp. (Nasdaq:MSFT) is gradually
becoming popular in educational institutions across Europe. Its Office 365
suite has won several customers such as School Center Skofja Loka (Slovenia),
TEI Kalamata (Greece), EDUCATIVA (Romania), Kozminski University (Poland),
Faculty of Economics and Business (Slovenia), University of Maribor and
Vaikystes Sodas (Lithuania).
The suite won on different counts at these institutions. While School Center
Skofja Loka wants to increase its visibility in the education sector,
employees at EDUCATIVA want to efficiently respond to thousands of emails
about its products and services. TEI Kalamata is deploying Office 365 to
efficiently manage funds and resources to research. Kozminski University wants
to keep in touch with their students even when they graduate from the
University. University of Maribor wants to install Office 365 to increase
communication and collaboration with its strong base of 4,000 students and
The Office 365 suite equips these organizations with advanced technologies,
thereby improving operational efficiency and resource allocation. Not only
does it facilitate communication and collaboration among the organizations,
but also reduces their IT expenses.
Office 365 is sold as a service and therefore, generates ongoing revenues for
Microsoft instead of a one-time licensing fee. Launched in Dec, 2011, the new
Office comes with the traditional word processing, spreadsheets and email
Microsoft's Office 365 is gaining traction in the market as it recently
launched its online version focusing on touch devices. Further, it is being
deployed at the stores of retailers such as J. C. Penney Company Inc.
(NYSE:JCP) and U.K.-based Tesco as well as government departments such as the
Texas Department of Information Resources, which chose the software for
inter-departmental activities. The latest to jump on the bandwagon is the
International Federation of Red Cross and Red Crescent Societies (IFRC), which
also signed a MoU with Microsoft. Further, Microsoft's software is gaining
ground in the healthcare sector. The company continues to innovate, launching
separate versions for businesses and student communities.
Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook:
Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
Zacks Investment Research
800-767-3771 ext. 9339
SOURCE Zacks Investment Research, Inc.
Press spacebar to pause and continue. Press esc to stop.